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Hydroxymethylcytosines (hmC), one of several reported cytosine modiﬁcations, was recently found to be
enriched in embryonic stem cells and neuronal cells, and thought to play an important role in regulating
gene expression and cell speciﬁcation. However, unlike methylcytosines (mC), the fate of hmC beyond
DNA replication is not well understood. Here, to monitor the status of hmC during DNA replication, we
prepared a stable episomal vector-based monitoring system called MoCEV in 293T cells. The MoCEV sys-
tem containing fully hydroxymethylated-cytosine fragments revealed a signiﬁcant modiﬁcation towards
mC after several rounds of DNA replication. Strikingly this modiﬁcation was speciﬁcally observed at the
CpG sites (71.9% of cytosines), whereas only 1.1% of modiﬁed cytosines were detected at the non-CpG
sites. Since the unmodiﬁed MoCEV did not undergo any DNA methylation during cell division, the results
strongly suggest that somatic cells undergo hmC to mC speciﬁcally at the CpG sites during cell division.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
DNA modiﬁcations are known to have critical roles in control-
ling and maintaining the pattern of chromatin structure, gene
expression and cell speciﬁcation. Methylation of DNA in mammals
is a well-characterized modiﬁcation, which predominantly occurs
at the 5th-position of cytosine in CpG dinucleotides (mCpG). This
epigenetic modiﬁcation has been thought to play an important role
in gene regulation and it is highly correlated to a variety of human
diseases such as cancers and imprinting disorders [1–6]. In addi-
tion to the commonly known methylcytosine (mC), the existence
of 5-hydroxymethylcytosine (hmC), which is produced through
the oxidation of mC by the ten–eleven translocation family of diox-
ygenases, was recently reported in mammalian cells [7,8].
Although hmC is widely detected in many tissues and cell types,
differential hmC contents were observed across multiple tissues,
which is contrary to the mC class [9]. The integration of genomicY-NC-ND license. 
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, MD 21205, USA.hmC signals with a histone enrichment map suggested that hmC
might play diverse roles in regulating speciﬁc promoters, gene
bodies and enhancers in embryonic stem cells (ESCs) [10]. Also,
since it has been reported that mCpG binding proteins do not inter-
act with hmC containing DNA substrates [11,12], modiﬁcations of
methylation and hydroxymethylation are likely to play distinct
roles in biological systems [13]. During the cell proliferation, the
mC type on the daughter strand of DNA is methylated by DNA
methyltransferase 1 (DNMT1), while the fate of hmC during cell
propagation remains unclear. One report showed the persistence
of hmC in ESCs beyond DNA replication [14], suggesting that ESCs
may require the existence of hmC after DNA replication. On the
other hand, hmC in mouse preimplantation embryos, which have
relatively low expression levels of DNMTs than the other cells,
reported loss of hmC during DNA replication [15]. Here, to address
the fate of hmC in somatic cells, we improved a previously
reported episomal plasmid-based method [16] to monitor hmC
status of any desired DNA fragments beyond DNA replication using
293T cells.2. Materials and methods
2.1. Cell culture
Human embryonic kidney cell line, 293T, was provided from
Cell Bank of RIKEN BioResource Center. 293T cells were grown in
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mented with 10% fetal bovine serum and 1% penicillin/streptomy-
cin (Life Technologies, Grand Island, NY) and were incubated at
37 C in a humidiﬁed 5% CO2 incubator.
2.2. PCR products with cytosine modiﬁcation
The 1.8 kbp of CAG promoter sequence, a strong promoter con-
sisting of chicken b-actin promoter and cytomegalovirus early en-
hancer element, with vector shared homologous 15-bp fragments
on both ends was obtained by PCR amplifying the pEBMulti-Hyg/
Venus+ vector as a template and speciﬁc primers (50-TTGA-
TTATTGACTAGTTATTAATAGTAATCAATTAC-30, 50-CCGCTCTAGAAC-
TAGTGGATCCCCCGGGCTGCAGG-30) using PrimeSTAR GXL DNA
polymerase (Takara Bio, Otsu, Japan). To make a CpG methylated
CAG promoter, 1 lg of PCR product was treated with 4 units M.SssI
CpG methyltransferase (New England BioLabs, Ipswich, MA) to-
gether with 0.64 mM S-adenosylmethionine at 37 C for 4 h, fol-
lowed by puriﬁcation using QIAquick PCR puriﬁcation kit
(Qiagen, Valencia, CA). Fully hmC modiﬁed linear CAG promoter
product was generated using hydroxymethyl dCTP (Nippon gene,
Tokyo, Japan) in PCR ampliﬁcations and puriﬁed using QIAquick
PCR puriﬁcation kit.
2.3. Transfection of In-fusion-based constructed vector with cytosine
modiﬁed DNA fragments
For a new construct of vector, pEBMulti-Hyg/Venus+/Promoter-
less, the EB virus based pEBMulti-Hyg expression vector [17]
(Wako Pure Chemical Industries) was modiﬁed. To perform In-Fu-
sion assembly, 9 lg of pEBMulti-Hyg/Venus+/Promoterless vector
was digested overnight by SpeI and puriﬁed by phenol/chloroform
extraction, followed by resuspension in a total volume of 45 ll of
autoclaved water. Four-microliters of puriﬁed PCR product of
CAG promoter as described above, 800 ng of the puriﬁed vector
and 8 ll of 5x In-Fusion HD enzyme (Takara Bio) were mixed
and incubated at 50 C for 15 min [18]. To transfect assembled vec-
tor into 293T cells, the samples were puriﬁed by phenol/chloro-
form extraction and ethanol precipitation, and then resuspended
in 50 ll Opti-MEM (Life Technologies). Two-microliter of Lipofect-
amine 2000 (Life Technologies) was diluted into 50 ll Opti-MEM
and kept for 5 min at room temperature. The preincubated Lipo-
fectamine 2000 solution was mixed with 50 ll of the In-Fusion
assemble samples in Opti-MEM and incubated for 30 min. For
the transfection, the cells were plated in 24 well plate at a density
of 5  104 293T cells per well and the medium was exchanged for
400 ll Opti-MEM just before transfection, followed by addition of
the incubated mixture of the assembled vector and Lipofectamine.
The transfected 293T cells were cultured in Opti-MEM for 24 h be-
fore replacing it by DMEM medium with 250 lg/ml Hygromycin B
(Life Technologies).
2.4. Bisulﬁte sequencing
Genomic DNAs from all episomal vector transfected 293T cells
were isolated with the NucleoSpin Tissue (Macherey-nagel, Düren,
Germany). Bisulﬁte treatment for 400 ng of each genomic DNA was
performed using an EZ DNA Methylation-Gold Kit in accordance
with the manufacturer’s instructions (Zymo Research, Irvine, CA).
The converted samples were ampliﬁed by Blend Taq Plus (Toyobo,
Tokyo, Japan) using speciﬁc primers as follows: Region1 (50-TT
GTATTAATTAATTGAAGGGATTATATGT-30 and 50-AAAATCATATAC-
TAAACATAATACCAAAC-30), Region2 (50-AAAGAATTAATTTTTATT
AAAGGGGTAT-30 and 50-AAATCAACTTCAAAATCAACTTACC-30). The
PCR amplicons were subcloned into TArget vector (Toyobo) and
isolated clones were sequenced using ABI3730xl DNA Analyzer(Life technologies). Visualization of bisulﬁte sequence data for
CpG methylation was performed using the QUMA web-based tool
[19].
2.5. Determination of the existence of hmC
The presence of hmC at speciﬁc MspI sites were analyzed using
EpiMark 5-hmC and 5-mC Analysis Kit (New England BioLabs) fol-
lowing the manufacturer’s recommended protocol, followed by
quantitative real-time PCR. Genomic DNA from 293T-CAG-hmC
and control DNA, which was provided in the kit, was treated with
T4 b-glucosyltransferase (T4-BGT) in the presence of UDP-glucose
in parallel with a mock reaction containing only UDP-glucose.
Then, one fourth of test and control reactions were digested with
MspI. Whereas MspI cleave a recognition sequence (CCGG) con-
taining either mC or hmC, glucosylated hmC containing MspI site
is resistant to the digestion. The real-time PCR analyzed the
amount of DNA template cut by MspI with/without T4-BGT
treatment using speciﬁc primers for 293T-CAG-hmC genomic
DNA (50-CGGGCCCCCCCTCGAGGTCG-30 and 50-GCCGCTCTAGAAC-
TAGTGG-30) or the manufacturer provided primers for control
DNA (50-CAGTGAAGTTGGCAGACTGAGC-30 and 50-CTGACTTGC-
CACCTATAGACAGC-30). Relative quantiﬁcation of hmC was
calculated as the ratio of the real-time PCR results (Ct [non-glu-
cosylated samples]/Ct [glucosylated samples]).
2.6. MBD real-time PCR
Genomic DNA from 293T-CAG-C, 293T-CAG-hmC and 293T-
CAG-mCpG were prepared using NucleoSpin Tissue Kits. One-
microgram of isolated genomic DNA was sonicated for 5 min with
a Branson 450 Sonicator (Branson Ultrasonics, Danbury, CT). PCR
products (CAG-C, CAG-hmC or CAG-mC) were mixed human geno-
mic DNA and fragmented by Covaris S2 sample preparation instru-
ment system (Covaris, Woburn, MA) as control fragments. Sheared
genomic DNA or control fragments was subjected to methyl-CpG
binding domain DNA capture (MBD) using the MethylMiner Meth-
ylated DNA Enrichment Kit (Life Technologies) following the man-
ufacturer’s recommended protocol. The bound fraction was eluted
by proteinase K and puriﬁed on a Qiaquick MinElute column (Qia-
gen, Valencia, CA). Real-time PCR reaction were carried out using
SYBR Premix ExTaq (Takara Bio) and speciﬁc primers for control
fragments (50-GCTAACCATGTTCATGCCTTC-30 and 50-TGCCAAAAT-
GATGAGACAGC-30) or for genomic DNA from 293T-CAG-C, 293T-
CAG-hmC or 293T-CAG-mCpG (50-CGATAAGCTTGATATCGAATT-
CCT-30 and 50-CTCACCATGGTTGTGGGGTA-30) on the ABI PRISM
7500 Fast Real-Time PCR System (Life technologies) by denatur-
ation at 95 C for 10 s, followed by running for 40 cycles at 95 C
for 5 s and 64 C for 30 s. The amount of target DNA recovered in
the captured fraction was quantiﬁed by calculating the percent
input recovery.3. Results
3.1. Preparation of an In-fusion-based vector construction method for
cytosine modiﬁed DNA fragments
Hsieh and colleagues had previously reported that methylated
DNA patches on the episomal plasmid are stably maintained for
a long period after transfection into human somatic cells [16].
However, the restriction enzyme digestion-based system is not
suitable for PCR products containing fully modiﬁed cytosines
because the cleavage site is blocked when a cytosine in the enzyme
recognition site is modiﬁed. To develop a more simple and effective
method to directionally incorporate cytosine-modiﬁed PCR
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ables fast directional cloning without the additional restriction en-
zyme digestion step (Fig. 1). To check the assembly reaction rates
between the inserts with and without mCpG, we performed the
In-fusion reaction with the in vitro methylated and untreated
CAG promoters, respectively. The number of transformed colonies
on LB plates resulted in no difference between the two vectors
(data not shown). Then, to examine whether the In-fusion
assembled vectors maintain the status of DNA methylation
in vivo, 5  104 293T cells were transfected with the mCpG or
unmodiﬁed promoter carrying vectors, and were grown to more
than 1  107 cells, replicating more than 7 times in average during
the cultivation. Subsequently, we performed down-stream gene
expression analysis, bisulﬁte sequencing and 5-aza-20-deoxycyti-
dine treatments, and revealed that CpG DNA methylation status,
both DNA methylated and unmethylated, were stably maintained
throughout replication (Supplemental Figs. S1–S4). We thus estab-
lished an In-fusion-based vector construction methods for cytosine
modiﬁed DNA fragments designated as MoCEV (Modiﬁed Cytosine
in Episomal Vector).3.2. Observation of hmC status beyond DNA replication
Next, to observe the status of hmC throughout multiple cell
divisions in 293T cells, we ﬁrst synthesized CAG promoter contain-
ing fully hydroxymethylated-cytosine by replacing deoxycytidine
triphosphates with 5-hydroxymethyl-deoxycytidine triphosphates
using PCR. For checking the incorporation of hmC, PCR products
were digested with the cytosine-modiﬁcation sensitive restriction
enzymes, HhaI and HpaII. Reasonably, the unmodiﬁed CAG pro-
moter was completely digested by both enzymes, while hmC con-
taining CAG promoter was resistant to these enzymes
(Supplemental Fig. S5A). In addition, the incorporation of hmC
was validated by the dot blots analysis using the antibody against
the hmC epitope (Supplemental Fig. S5B). The assembly reaction
rates were also analyzed, resulting in no difference in the number
of transformed colonies (data not shown). Thereafter, the MoCEV
containing hmC CAG promoter was transfected into 293T cells
(293T-CAG-hmC). In order to observe the maintenance of hmC
in vivo, genomic DNA from 293T-CAG-hmC was extracted after
2 weeks of cultivation and subjected to bisulﬁte treatment. The
bisulﬁte-treated samples were ampliﬁed in two regions (Region1
and Region2), including the vector junction and the CAG promoterOriP
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Fig. 1. Schematic illustrations of the MoCEV system construction process. The pEBMulti
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cytosine. (For interpretation of the references to colour in this ﬁgure legend, the readersequences, followed by the nucleotide sequencing analysis (Sup-
plemental Fig. S3). The Region1 amplicon covered 79 cytosines
on the CAG promoter (17 CpGs and 62 non-CpGs across the 360-
bp region), and the Region2 amplicon contained 28 cytosines on
the CAG promoter (7 CpGs and 21 non-CpGs across the 220-bp
region). The hmC in the non-CpG contexts showed a higher fre-
quency of loss-of-resistance against bisulﬁte treatment (1232 out
of 1246 cytosines; 98.9%), indicating that hmC was changed to
cytosine predominantly at non-CpG residues (Fig. 2A and B). How-
ever, hmC in the CpG context showed a signiﬁcantly dense bisulﬁte
resistant cytosine. We found that 71.9% of CpG in the 293T-CAG-
hmC vectors were resistant to bisulﬁte treatment, while all of cyto-
sines were converted in 293T-CAG-C (Fig. 2B and C). This outcome
demonstrates that hmC in the CpG sites is selectively maintained
to resist bisulﬁte treatment throughout DNA replication.3.3. Determination of modiﬁed form of cytosines
Because bisulﬁte sequence analysis cannot distinguish hmC
frommC [20], we performedMspI restriction enzyme digestion fol-
lowed by real-time PCR to determine the existence of hmC. T4 b-
glucosyltransferase (T4-BGT) with UDP-glucose is able to add a
glucose group to the hydroxyl group of hmC. Unlike the MspI
cleavage sites in hmC, mC and unmodiﬁed cytosines, glucosylated
hmC cannot be cleaved by MspI (Fig. 3A). By applying this sensitiv-
ity change, real-time PCR was used to determine the amount of
DNA template digested by MspI before and after the treatment
with T4-BGT, allowing the quantiﬁcation of hmC levels at the MspI
sites [19]. As shown in Fig. 3B, we found clear changes in the en-
zyme digestion rates of hmC control fragments after T4-BGT treat-
ments. However, although 63.6% of cytosines at the MspI sites
were resistant to bisulﬁte treatment in 293T-CAG-hmC (Fig. 2C,
blue box), no difference was observed between unglucosylated
and glucosylated DNA from 293T-CAG-hmC, suggesting that the
bisulfate resistant cytosine at the MspI site is not hmC. Because
the above analysis showed modiﬁcation of only one cytosine resi-
due at the MspI site, we further examined the modiﬁcation of en-
tire hmC. We prepared a DNA precipitation method using the
methyl binding Domain 2 (MBD2) protein, followed by the ampli-
ﬁcation of the Region2 using real-time PCR (MBD real-time PCR).
Since MBD2 has no afﬁnity for hmC and unmodiﬁed cytosine
[11], in vitro synthesized control DNA fragments of CAG-mCpG
were enriched higher than those of CAG-C and CAG-hmC bypEBMulti-Hyg/ 
Venus+/ 
odified Promoter
M M M M M M
Direct Transfection
> 2 weeks culture
-Hyg/Venus+/Promoterless vector contains a SpeI recognition sequence (A|CTAGT).
cations were assembled by the In-fusion treatment to produce the pEBMulti-Hyg/
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analysis revealed that using sheared DNA samples from 293T-
CAG-C, 293T-CAG-mCpG and 293T-CAG-hmC, and the precipitated
DNA from 293T-CAG-hmC showed almost the same enrichment to
that of 293T-CAG-mCpG, but not from 293T-CAG-C (Fig. 4B). Col-
lectively, these data revealed that most of the bisulﬁte resistant
cytosines at the CpG sites of CAG promoter were methylcytosines.4. Discussion
The hmC was initially discovered as a new constituent of
mammalian DNA [7,8]. Current studies suggested that hmC might
play a role in regulating the status of DNA methylation [21]. Guo
and colleagues previously demonstrated a replication-independent
hmC-to-cytosine transformation using hmC-modiﬁed green
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lowing this report, we hypothesized that a few bisulﬁte-resistant
cytosines would be detected using the MoCEV system during sev-
eral cycles of DNA replication in 293T cells. But to our surprise,
bisulﬁte-resistant cytosines in the CpG sites, but not in non-CpG,
were clearly detected. Moreover, our experimental results notably
indicated that bisulﬁte-resistant cytosines in the CpG sites were
mainly mCpGs after the several rounds of DNA replication. Since
we showed that both methylated and unmethylated cytosines on
the MoCEV were maintained beyond DNA replication (Supplemen-
tal Fig. S3), hydroxymethylated CpGs in the parental strand may
dictate methylation sites on the daughter strand in somatic cells,
which is consistent with the enrichment of hmC in non-prolifera-
tive neuronal cells (Fig. 4C). These ﬁndings suggest the existence
of molecular machinery for hemi-hydroxymethylated CpG recogni-
tion. Although further experiments are needed to elucidate the
mechanisms of this ﬁnding, we speculate that the maintenance
DNMTs may participate in the alteration of hmC to mC at the
CpG regions. In mammals, three catalytically active DNMTs have
been identiﬁed and characterized. DNMT1 is responsible for the
maintenance of DNA methylation pattern beyond DNA replication,
whereas, DNMT3A and DNMT3B are de novo methyltransferases
that have activities for establishing cytosine methylation patterns
at unmethylated CpG sites. Valinluck and Sowers reported that
hmC prevents DNMT1 recognition in vitro [23], however, UHRF1,
an essential factor in DNA methylation maintenance, was reported
to recognize hemi-hydroxymethylated CpG sites as well as hemi-
methylated CpG sites [24]. This report suggested that UHRF1
may bind to the hemi-hydroxymethylated CpG sites and recruit
DNMT1 to newly methylated CpGs in the daughter strand after
DNA replication. On the other hand, Hashimoto and colleagues re-
ported that DNMT3A and DNMT3B were capable of acting on the
hemi-hydroxymethylated CpG site in vitro [25]. However, since
293T cells have low expression of DNMT3A, DNMT3B and DNMT3L
according to the public expression database [26], DNMT3 proteins
may not contribute to the alteration of hmC to mC in 293T cells.
In this study, we established the In-fusion based MoCEV system,
which is simple and stable method to track modiﬁed cytosines. We
believe that the MoCEV system may help to further elucidate the
functionalmechanismand regulatorymechanisms of cytosinemod-
iﬁcation during cell proliferation as well as differentiations. ESCs,
which have relatively high levels of hmC and maintain them after
DNA replication [27], are one of good cell model for these experi-
ments. For instance, since the study of genome-wide distribution
of hmC as well as mC was published [28], we are able to select the
desired regions that are enriched for cytosinemodiﬁcations in ESCs.
In addition, since 5-formylcytosine and 5-carboxylcytosine were
identiﬁed as new constituents of mammalian DNA [29,30], the Mo-
CEV system also has great potentials to facilitate numerous research
applications for cytosine modiﬁcation and DNA demethylation.
In conclusion, to investigate the fate of hmC after DNA replica-
tion, we ﬁrst prepared a simple and stable episomal vector-based
system to monitor the status of cytosine modiﬁcation, and we suc-
cessfully demonstrated the maintenance of DNA methylation sta-
tus at the CpG sites throughout multiple cell divisions. Using the
system, we revealed that mCs were observed at the hydroxyme-
thylated CpG sites, whereas the modiﬁcation was not detected in
the non-CpG sites after several rounds of DNA replication in
293T cells. This observation indicated somatic cells undergo hmC
at the CpG sites to mC during cell division and is important to
understand the regulation of DNA modiﬁcation.
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